摘要
目的:观察早期应用辛伐他汀强化治疗对急性冠状动脉综合征(ACS)患者血小板氧化低密度脂蛋白内皮受体-1(LOX-1)表达和近期预后的影响。方法:87例ACS患者随机分为A、B组,A组患者在常规药物治疗基础上早期给予辛伐他汀20mg/晚,B组患者在常规药物治疗基础上早期给予辛伐他汀60mg/晚,入院后次日及1周后采血检测肝肾功能、血糖、血脂、血小板聚集功能、血小板LOX-1的表达,观察入院后30d内主要心血管事件。结果:治疗后2组患者血小板LOX-1水平均有明显下降,B组下降更明显,2组比较差异有统计学意义(2.91±0.65∶2.61±0.51,P<0.05)。治疗后2组患者血小板聚集功能均有明显下降,B组降低更明显,2组比较差异有统计学意义(34.2±11.1∶29.4±7.7,P<0.05)。B组较A组30d内主要心血管事件发生更低。结论:早期强化他汀类药物治疗ACS患者短期内能抑制血小板功能,改善患者的近期预后,这可能与抑制血小板LOX-1的表达有关。
Objective:To observe the effect of early intensified use of simvastatin treatment on platelet oxidized low-density lipoprotein receptor-1( LOX-1) expression and short-term prognosis,in patients with acute coronary syndrome. Method:Eighty-seven cases with ACS were randomly divided into A,B group,Patients in A group based on conventional drug therapy was given simvastatin 20 mg/night,patients in B group based on conventional drug therapy was given simvastatin 60 mg/night Blood liver and kidney function,blood sugar,blood lipids,platelet aggregation,platelet expression of LOX-1 was tested on the first day after admission and the day after a week,major cardiovascular events was observed within 30 days after admission.Result:After a week,both groups have decreased platelet aggregation,B group reduced more significantly than A group (34.2±11.1 vs 29.4±7.7,P〈0.05). The platelet LOX-1 levels were significantly decreased in two groups after treatment too,B group decreased more significantly(2.91±0.65 vs 2.61±0.51,P〈0.05). Major cardiovascular events within 30 days after admission occurred less in group B.Conclusion:The early intensive simvastatin therapy in patients with acute coronary syndrome can inhibit platelet function and improve short-term prognosis of patients,it may work by inhibiting platelet LOX-1 expression.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2010年第2期121-123,共3页
Journal of Clinical Cardiology
基金
广西柳州市科学研究与技术开发计划项目(No:2008031415)